Literature DB >> 19079736

Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Chung-Pu Wu1, Anna Maria Calcagno, Suresh V Ambudkar.   

Abstract

Overexpression of ATP-binding cassette (ABC) drug transporters that actively efflux a variety of amphipathic compounds can cause multidrug resistance (MDR) in cancer cells, which is a major obstacle in the success of cancer chemotherapy. The development of synthetic small molecule compounds or the identification of natural products that block ABC transporter-mediated efflux has been the conventional approach used to combat MDR. The strategy of using chemosensitizers, however, has not been successful in clinical cancer chemotherapy. Therefore, alternative approaches to identify or to synthesize compounds that can induce selective toxicity in cancer cells overexpressing one or more ABC transporters have been undertaken. This review summarizes the recent advances in identifying strategies to restore sensitivity to chemotherapeutics in multidrug resistant cancer cells.

Entities:  

Keywords:  ATP-binding cassette transporters; Chemosensitizers; Collateral sensitivity; Modulators; Multidrug resistance

Mesh:

Substances:

Year:  2008        PMID: 19079736      PMCID: PMC2600768          DOI: 10.2174/1874467210801020093

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  173 in total

1.  New triazine derivatives as potent modulators of multidrug resistance.

Authors:  A Dhainaut; G Régnier; G Atassi; A Pierré; S Léonce; L Kraus-Berthier; J F Prost
Journal:  J Med Chem       Date:  1992-06-26       Impact factor: 7.446

2.  In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

Authors:  D Boesch; C Gavériaux; B Jachez; A Pourtier-Manzanedo; P Bollinger; F Loor
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

3.  Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis.

Authors:  Tavan Janvilisri; Henrietta Venter; Sanjay Shahi; Galya Reuter; Lekshmy Balakrishnan; Hendrik W van Veen
Journal:  J Biol Chem       Date:  2003-03-28       Impact factor: 5.157

4.  Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas.

Authors:  S E Bates; C Y Shieh; L A Mickley; H L Dichek; A Gazdar; D L Loriaux; A T Fojo
Journal:  J Clin Endocrinol Metab       Date:  1991-07       Impact factor: 5.958

5.  A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity.

Authors:  Joel Karwatsky; Maximilian C Lincoln; Elias Georges
Journal:  Biochemistry       Date:  2003-10-28       Impact factor: 3.162

6.  P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.

Authors:  Claudina Alemán; Jean-Philippe Annereau; Xing-Jie Liang; Carol O Cardarelli; Barbara Taylor; Jun Jie Yin; Adorjan Aszalos; Michael M Gottesman
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

7.  The role of breast cancer resistance protein in acute lymphoblastic leukemia.

Authors:  Sabine L A Plasschaert; Dorina M van der Kolk; Eveline S J M de Bont; Willem A Kamps; Kuniaki Morisaki; Susan E Bates; George L Scheffer; Rik J Scheper; Edo Vellenga; Elisabeth G E de Vries
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

8.  Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected].

Authors:  P R Twentyman; N M Bleehen
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

Authors:  J Verweij; H Herweijer; R Oosterom; M E van der Burg; A S Planting; C Seynaeve; G Stoter; K Nooter
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more
  89 in total

1.  Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.

Authors:  Gauri Patwardhan; Vineet Gupta; Juowen Huang; Xin Gu; Yong-Yu Liu
Journal:  Biochem Pharmacol       Date:  2010-03-16       Impact factor: 5.858

2.  Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.

Authors:  Haiyang Chen; Kazuhiko Shien; Ken Suzawa; Kazunori Tsukuda; Shuta Tomida; Hiroki Sato; Hidejiro Torigoe; Mototsugu Watanabe; Kei Namba; Hiromasa Yamamoto; Junichi Soh; Hiroaki Asano; Shinichiro Miyoshi; Shinichi Toyooka
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

3.  The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

Authors:  Sung-Han Hsiao; Sabrina Lusvarghi; Yang-Hui Huang; Suresh V Ambudkar; Sheng-Chieh Hsu; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2019-01-11       Impact factor: 8.679

4.  Novel cGMP efflux inhibitors identified by virtual ligand screening (VLS) and confirmed by experimental studies.

Authors:  Georg Sager; Elin Ø Ørvoll; Roy A Lysaa; Irina Kufareva; Ruben Abagyan; Aina W Ravna
Journal:  J Med Chem       Date:  2012-03-20       Impact factor: 7.446

5.  The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.

Authors:  Sung-Han Hsiao; Megumi Murakami; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2018-07-18       Impact factor: 8.679

Review 6.  Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

Authors:  Tao Hu; Zhen Li; Chun-Ying Gao; Chi Hin Cho
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

7.  Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

Authors:  Tong Shen; Ye-Hong Kuang; Charles R Ashby; Yu Lei; Angel Chen; Ying Zhou; Xiang Chen; Amit K Tiwari; Elizabeth Hopper-Borge; Jiangyong Ouyang; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

8.  The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy.

Authors:  Olga A Patutina; Nadezda L Mironova; Nelly A Popova; Vasily I Kaledin; Valery P Nikolin; Valentin V Vlassov; Marina A Zenkova
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

Review 9.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

10.  TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.

Authors:  Rosa S Schneiderman; Esther Shmueli; Eilon D Kirson; Yoram Palti
Journal:  BMC Cancer       Date:  2010-05-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.